

DUPILUMAB TREATMENT LEADS TO RAPID AND CONSISTENT IMPROVEMENT OF ATOPIC DERMATITIS IN ALL ANATOMICAL REGIONS IN PATIENTS AGED 6 MONTHS TO 5 YEARS


Elaine C. Siegfried, Eric L. Simpson, Michael J. Cork, Peter D. Arkwright, Lara Wine Lee, Zhen Chen, Randy Prescilla, Ashish Bansal, Noah A. Levit, Ainara Rodríguez Marco

Dermatology and Therapy

Background


Atopic dermatitis (AD) is heterogeneous in distribution pattern and often affects infants and young children differently than older patients.

Study design




Results

EASI¹ REGIONAL SCORE



INDIVIDUAL EASI SIGN SCORES



Dupilumab led to significant improvements in excoriations, infiltration/papulation, and erythema in all anatomical regions by week 2, and in lichenification by week 4.

1. EASI, Eczema Area and Severity Index.

Conclusion

Dupilumab treatment rapidly improved AD signs and severity equally well across different anatomical regions in children aged 6 months to 5 years with moderate-to-severe AD. Dupilumab was generally well tolerated with an acceptable safety profile.

